Skip to main content
NAMS
NASDAQ Life Sciences

NewAmsterdam's Obicetrapib Clears Key EU Hurdle with Positive CHMP Opinion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$31.35
Mkt Cap
$3.571B
52W Low
$21.135
52W High
$42.205
52W Position info
48% above low
Off High info
26% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NAMS sits 48% above its 52-week low of $21.135.

Summary

NewAmsterdam Pharma and partner Menarini received a positive CHMP opinion for obicetrapib monotherapy and its fixed-dose combination with ezetimibe, recommending EU marketing authorization. A final European Commission decision is expected in 2H26, triggering potential milestone payments and royalties.


Key Events · Product Development and Regulatory · NAMS

  • CHMP Recommends EU Approval

    The EMA's CHMP adopted a positive opinion for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimibe FDC) for primary hypercholesterolemia and mixed dyslipidemia, based on Phase 3 BROADWAY, BROOKLYN, and TANDEM data.

  • Commercial Opportunity in Europe

    Menarini holds exclusive European commercialization rights; NewAmsterdam is entitled to tiered double-digit royalties (low double-digits to mid-twenties) and up to €833 million in clinical, regulatory, and commercial milestones.

  • Next Regulatory Step

    The European Commission is expected to issue a final marketing authorization decision in the second half of 2026, which would apply across all EU member states plus Iceland, Liechtenstein, and Norway.

  • Clinical Validation

    Obicetrapib demonstrated statistically significant LDL-C reductions of up to 40% as monotherapy and ~50% in combination with ezetimibe versus placebo, with a tolerability profile comparable to placebo.


Analysis · NAMS · Life Sciences

A positive CHMP opinion marks a pivotal regulatory milestone, placing obicetrapib on the cusp of EU marketing authorization. As the drug's first major regulatory decision, it validates the clinical profile and unlocks a path to commercialization in Europe. With a final European Commission decision expected in the second half of 2026, the event materially de-risks the obicetrapib program and opens a significant revenue stream through partner Menarini, including up to €833 million in milestones and tiered double-digit royalties. For a late-stage biotech with a $3.6 billion market cap, this is a thesis-altering event that shifts the focus from clinical development to commercial execution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAMS was trading at $31.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $21.14 to $42.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $18.32 info
Change: -$2.37 (-11%) info
Market Cap: $2.208B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $18.32 info
Change: -$1.92 (-9%) info
Market Cap: $2.208B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.32 info
Change: -$5.39 (-23%) info
Market Cap: $2.208B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $18.32 info
Change: -$5.00 (-21%) info
Market Cap: $2.208B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.32 info
Change: -$4.50 (-20%) info
Market Cap: $2.208B info